Literature DB >> 23456437

Do statins cause diabetes?

Mark R Goldstein1, Luca Mascitelli.   

Abstract

A wealth of evidence has established that cholesterol-lowering statin drugs, widely used for the prevention of cardiovascular disease, do increase the risk of new-onset diabetes, possibly by impairing pancreatic beta cell function and decreasing peripheral insulin sensitivity. Groups at particular risk include the elderly, women, and Asians. The diabetogenic effect of statins appear directly related to statin dose and the degree of attained cholesterol lowering. Statins can cause hyperinsulinemia even in the absence of hyperglycemia and the potential mitogenic effects and implications of prolonged hyperinsulinemia are discussed. Suggestions are made as to how physicians might avert the hyperinsulinemic and diabetogenic effects of statin therapy in clinical practice, and modulate the detrimental effects of these drugs on exercise performance. Finally, long-term studies are needed to determine if the deleterious hyperinsulinemic and diabetogenic effects of statin therapy undermine the beneficial cardiovascular disease risk outcomes in various segments of the population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456437     DOI: 10.1007/s11892-013-0368-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  87 in total

1.  Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes.

Authors:  L H Chamberlain
Journal:  FEBS Lett       Date:  2001-11-02       Impact factor: 4.124

2.  Statin therapy in young adults: ready for prime time?

Authors:  Mark J Pletcher; Stephen B Hulley
Journal:  J Am Coll Cardiol       Date:  2010-08-17       Impact factor: 24.094

Review 3.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

Review 4.  PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity.

Authors:  Vitor A Lira; Carley R Benton; Zhen Yan; Arend Bonen
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-04-06       Impact factor: 4.310

5.  Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Authors:  Anthony Keech; David Colquhoun; James Best; Adrienne Kirby; R John Simes; David Hunt; Wendy Hague; Elaine Beller; Manjula Arulchelvam; Jennifer Baker; Andrew Tonkin
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

Review 6.  Metabolic effects of fructose and the worldwide increase in obesity.

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 7.  Effects of niacin on glucose control in patients with dyslipidemia.

Authors:  Ronald B Goldberg; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2008-04       Impact factor: 7.616

Review 8.  Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes.

Authors:  Beth A Parker; Paul D Thompson
Journal:  Exerc Sport Sci Rev       Date:  2012-10       Impact factor: 6.230

9.  Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis.

Authors:  Jessica A Alvarez; Ambika Ashraf
Journal:  Int J Endocrinol       Date:  2010       Impact factor: 3.257

10.  Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.

Authors:  Catherine C Cowie; Keith F Rust; Earl S Ford; Mark S Eberhardt; Danita D Byrd-Holt; Chaoyang Li; Desmond E Williams; Edward W Gregg; Kathleen E Bainbridge; Sharon H Saydah; Linda S Geiss
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

View more
  7 in total

1.  Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study.

Authors:  Kenneth A Lichtenstein; Rachel L D Hart; Kathleen C Wood; Samuel Bozzette; Kate Buchacz; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

2.  Sesamol protects MIN6 pancreatic beta cells against simvastatin-induced toxicity by restoring mitochondrial membrane potentials.

Authors:  Girish A Ghadge; Karthik Gourishetti; Mallikarjuna Rao Chamallamudi; Gopalan Kutty Nampurath; Krishnadas Nandakumar; Nitesh Kumar
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

3.  Diabetogenic effect of statins: a double-edged sword?

Authors:  Ji Sung Yoon; Hyoung Woo Lee
Journal:  Diabetes Metab J       Date:  2013-12       Impact factor: 5.376

Review 4.  Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion.

Authors:  Simón Quetzalcoatl Rodríguez-Lara; Ernesto German Cardona-Muñoz; Ernesto Javier Ramírez-Lizardo; Sylvia Elena Totsuka-Sutto; Araceli Castillo-Romero; Teresa Arcelia García-Cobián; Leonel García-Benavides
Journal:  Oxid Med Cell Longev       Date:  2016-12-28       Impact factor: 6.543

5.  Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials.

Authors:  Alaa J Rahal; Ahmed I ElMallah; Rita J Poushuju; Rana Itani
Journal:  Saudi Med J       Date:  2016-10       Impact factor: 1.484

6.  Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment.

Authors:  Erik Hallengren; Peter Almgren; Maria Rosvall; Gerd Östling; Margaretha Persson; Andreas Bergmann; Joachim Struck; Gunnar Engström; Bo Hedblad; Olle Melander
Journal:  BMC Cardiovasc Disord       Date:  2017-05-16       Impact factor: 2.298

7.  Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States.

Authors:  Brent M Egan; Jiexiang Li; Robert A Davis; Kevin A Fiscella; Jonathan N Tobin; Daniel W Jones; Angelo Sinopoli
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-05-18       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.